Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 2
Submit an article Journal homepage
106
Views
18
CrossRef citations to date
0
Altmetric
Review

Emerging drugs in assisted reproduction

Evangelos G PapanikolaouAZ-VUB, University Hospital, Dutch-speaking Brussels Free University Centre for Reproductive Medicine, Laarbeeklaan 101, 1090 Jette, BrusselsBelgiumTel: + 32 472 924 683; Fax: + 32 2 477 6607;E-mail: [email protected]
,
Efstratios KolibianakisAZ-VUB, University Hospital, Dutch-speaking Brussels Free University Centre for Reproductive Medicine, Laarbeeklaan 101, 1090 Jette, BrusselsBelgiumTel: + 32 472 924 683; Fax: + 32 2 477 6607;E-mail: [email protected]
&
Paul DevroeyAZ-VUB, University Hospital, Dutch-speaking Brussels Free University Centre for Reproductive Medicine, Laarbeeklaan 101, 1090 Jette, BrusselsBelgiumTel: + 32 472 924 683; Fax: + 32 2 477 6607;E-mail: [email protected]
Pages 425-440 | Published online: 10 May 2005

Bibliography

  • SPEROFF L, GLASS RH, KASE NG: Infertility. In: Clinical Gynecologic Endocrinology and Infertility (6th Ed). Lippincott Williams ec Wilkins, Baltimore, USA (1999):201–246.
  • HEALY DL, TROUNSON AO, ANDERSEN AN: Female infertility: causes and treatment. Lancet (1994) 343:1539–1544.
  • ABMA JC, CHANDRA A, MOSHER WD, PETERSON LS, PICCININO LJ: Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Vital Health Sten 23. (1997) 19:1–114.
  • LUNENFELD B, MENZI A, VOLET B: Clinical effects of human postmenopausal gonadotropins. Acta Endocrinol (1960) (Suppl.)51:587.
  • SMITZ J, DEVROEY P, BRAECKMANS P et al.: Management if failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and hMG. Hum. Reprod. (1987) 2:309–314.
  • DEVROEY P, VAN STEIRTEGHEM A, MANNAERTS B, BENNINK HC: Successful in-vitro fertilisation and embryo transfer after treatment with recombinant human FSH. Lancet (1992) 339: 1170.
  • ALBANO C, FELBERBAUM RE, SMITZ J et al.: Ovarian stimulation with HMG: results of a prospective randomized Phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. The European Cetrorelix Study Group. Hum. Reprod. (2000) 15:526–531.
  • BORN G, MANNAERTS B: Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum. Reprod. (2000) 15:1490–1498.
  • THE EUROPEAN RECOMBINANT LH STUDY GROUP HUMAN: Recombinant luteinizing hormone is as effective as; but safer than, urinary human chorionic gonadotropin in inducing final maturation and ovulation in vitro fertilization procedures: results of a multicenter double-blind study. J. Clin. Endocrinol. Metab. (2001) 86:2607–2618.
  • •A compehensive randomised study comparing recLH and uHCG for inducing final oocyte maturation.
  • STEPTOE PC, EDWARDS RG: Birth after the reimplantation of a human embryo. Lancet (1978) 2:366.
  • LOPATA A, JOHNSTON IW, HOULT IJ, SPEIRS Al : Pregnancy following intrauterine implantation of an embryo obtained by in vitro fertilization of a preovulatory egg. Fend. Steril. (1980) 33:117–120.
  • PALERMO G, JORIS H, DEVROEY P, VAN STEIRTEGHEM AC: Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet (1992) 340: 17–18.
  • ADAMSON D, LANCASTER P, DE MOUZON J, NYGREN KG, ZEGERS-HOCHSHIELD F : INTERNATIONAL WORKING GROUP for REGISTERS on ASSISTED REPRODUCTION (IFFS TASK FORCE): World collaborative report on assisted reproductive technology, 1998. In: Reproductive medicine in the twenty-first century. Healy DL, Kovacs GT, McLachlan R, Rodrigues-Armas O (Eds). Proceedings of the 17th World Congress on Fertility and Sterility, Melbourne Australia. Parthenon, New York, USA (2002):209–219.
  • LLOYD A. KENNEDY R, HUTCHINSON J, SAWYER W: Economic evaluation of higly purified menotropin compared with recombinant follicle stimulating hormone in assisted reproduction. Fend Steril (2003) 80:1108–1113.
  • PAPANIKOLAOU EG, TOURNAYE H, VERPOEST W et al.: Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum. Reprod. (2005) 20:636–641.
  • URBANCSEK J, RABE T, STROWITZKI T: Ovarian stimulation for in vitro fertilization: past and present. In: Manual on Assisted Reproduction. Rabe T, Diedrich K, Strowitzki T (Eds). Springer-Verlag Heidelberg, Germany (2000):165–195.
  • NYGREN KG, ANDERSEN AN: Assisted reproductive technology in Europe, 1999. Results generated from European registers by ESHRE. Hum. Reprod. (2002) 17:3260–3274.
  • DEVROEY P, BOURGAIN C, MACKLON NS, FAUSER BC: Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab. (2004) 15:84–90.
  • FAUSER BC, DEVROEY P: Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. (2003) 14:236-242. A review of the consequences of ovarian stimulation on the luteal phase and endometrial receptivity.
  • LOPATA A, BROWN JB, LEETON JF, TALBOT JM, WOOD C: In vitro fertilization of preovulatory oocytes and embryo transfer in infertile patients treated with clomiphene and human chorionic gonadotropin. Fertil. Steril (1978) 30:27–35.
  • MESSINIS IE: Drugs used in in vitro fertilisation procedures. Drugs (1989) 38:148–59.
  • •This paper introduces the first steps of IVF.
  • LUNENFELD B, LUNENFELD E, INSLER V: Human Gonadotropins. In: Manual on Assisted Reproduction. Rabe T, Diedrich K, Strowitzki T (Eds). Springer-Verlag Heidelberg, Germany (2000):79–132.
  • LUNENFELD B, SULIMOVICI S, RABAU E, ESHKOL k Einduction de l'ovulation dans les amenorrhees hypophysaies par un traitement combine de gonadotropines urinaires menopausiques et de gonadotropines chorioniques. Soc. Fr. GynecoL (1962) 5: 346–351.
  • DICKEY RP, THORNTON M, NICHOLS J, MARSHALL DC, FEIN SH, NARDI RV; BRAVELLE IVF STUDY GROUP: Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-beta for in vitro fertilization: a prospective, randomized study. Fend Steril (2002) 77:1202–1208.
  • CHUONG CJ, YOUNG RI,, BOESCH CL, LEWALLEN NB, REILLY M: Successful pregnancy after treatment with recombinant human follicle stimulating hormone. Lancet (1993) 341:8852.
  • GOLDFARB JM, DESAI N: Follitropin-aversus human menopausal gonadotropin in an in vitro fertilisation program. Fend Steril (2003) 80:1094–1099.
  • OUT HJ, DRIESSEN SG, MANNAERTS BM, COELINGH BENNINK HJ: Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in-vitro fertilization than urinary gonadotropins. Fend Steril (1998) 69(Suppl. 1):540–544.
  • •A randomised controlled study comparing the effects of rFSH with urinary gonadotrophins with respect to pregnancy rates.
  • DAYA S: Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fend Steril (2002) 77:711–714.
  • VAN WELY M, WESTERGAARD LG, BOSSUYT PM, VAN DER VEEN F: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst. Rev. (2003) 1:CD003973.
  • AL-INANY H, ABOULGHAR M, MANSOUR R, SEROUR G: Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum. Reprod. (2003) 18:305–313.
  • THE EUROPEAN RECOMBINANT HUMAN LH STUDY GROUP: Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose- finding study./ Clin. Endocrionol. Metab. (1998) 83:1507–1514.
  • FERRARETTI AP, GIANAROLI L, MAGLI MC, D'ANGELO A. FARFALLI V MONTANARO N: Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fend Steril (2004) 8:1521–1526.
  • DE PLACIDO G, ALVIGGI C, PERINO A et al.: Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum. Reprod. (2005) 20(2):390–396.
  • KOLIBIANAKIS EM, ZIKOPOULOS K, SCHIETTECATTE J et al.: Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum. Reprod. (2004) 19:2490–2496.
  • SMITZ J, RON-EL R, TARLATZIS BC: The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres. Hum. Reprod. (1992) 7(Suppl. 1):49–66.
  • TARLATZIS B, BILI H: Safety of GnRH agonists and antagonists. Expert Opin. Drug Stif (2004) 3:39–46.
  • •Reviews safety issues with regards to the use of GnRH analogues in ART.
  • HUIRNE JA, LAMBALK CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet (2001) 358:1793–1803.
  • SHAPIRO DB: An overview of GnRH antagonists in infertility treatments. Introduction. Fend. Steril. (2003) 80\(Suppl. 1):S1–57.
  • AL-INANY H, ABOULGHAR M: GnRH antagonist in assisted reproduction: a Cochrane review. Hum. Reprod. (2002) 17:874–885.
  • KOLIBIANAKIS EM, ZIKOPOULOS K, SMITZ J et al.: Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum. Reprod. (2004) 7:1525–1529.
  • LUDWIG M, DOODY KJ, DOODY KM: Use of recombinant human chorionic gonadotropin in ovulation induction. Fend Steril (2003) 79:1051–1059.
  • ABDALLA IH, AH-MOYE M, BRISDEN P, HOWE DL, OKONOFUS F, CRAFT I: The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fend Steril (1987) 48:958–963.
  • THE EUROPEAN RECOMBINANT HUMAN CHORIONIC GONADOTROPHIN STUDY GROUP: Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment-recombinant HCG versus urinary HCG. Hum. Reprod. (2000) 15:1446–1451.
  • HUGUES JN: Comparative use of urinary and recombinant human chorionic gonadotropins in women. Treat. Endocrinol (2004) 3:371–379.
  • BELAISCH-ALLART J, DE MOUZON J, LAPOUSTERLE C, MAYER M: The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF program. Hum. Reprod. (1990) 5:163–166.
  • MOCHTAR MH, HOGERZEIL HV, MOL BW: Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cy• des. a randomized clinical trial. Hum. Reprod. (1996) 11: 1602–1605.
  • FRITTS EA, ATWOOD AK: Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum. Reprod. (2002) 17:2287–2299.
  • ••An excellent review on lutealsupplemantation treatments.
  • TAVANIOTOU A, SMITZ J, BOURGAIN C, DEVROEY P: Comparison between different routes of progesterone administration as luteal phase support in infertility treatment. Hum. Reprod. Update (2000) 6:139–148.
  • SMITZ J, DEVROEY P, FAGUER B, BOURGAIN C, CAMUS M, VAN STEIRTEGHEM AC: A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum. Reprod. (1992) 7: 168–175.
  • SMITZ J, BOURGAIN C, VAN WAESBERGHE L, CAMUS M, DEVROEY P, VAN STEIRTEGHEM AC: A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Hum. Reprod. (1993) 8:40–45.
  • LEWIN A, BENSHUSHAN A, MEZKER E, YANAI N, SCHENKER JG, GOSHEN R: The role of estrogen support during the luteal phase of in vitro fertilization-embryo transfer transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fend Steril (1994) 62:121–125.
  • FARHI J, -WEISSMAN A, STEINFELD Z,SHORER M, NAHUM H, LEVRAN D: Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril (2000) 73:761–766.
  • DEVROEY P, FAUSER BC, PLATTEAU P, BECKERS NG, DHONT M, MANNAERTS BM: Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin-a) for controlled ovarian stimulation before in vitro fertilization. J. Clin. Endocrinol. Metab. (2004) 89:2062–2070.
  • KLEIN J, LOBEL L, POLLAK S et al.: Development and characterization of a long-acting recombinant hFSH agonist. Hum. Reprod. (2003) 18:50–56.
  • MITWALLY MF, CASPER RF: Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr. Opin. Obstet. GynecoL (2002) 14:255–263.
  • ORVIETO R: Can we eliminate severe ovarian hyperstimulation syndrome. Hum. Reprod. (2005) 20(2):320–322. A very interesting article on severe OHSS and its prevention.
  • MCKENNA SD, PIETROPAOLO M, TOS EG et al.: Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in FSH-primed rats. Endocrinology (2005)(1):208–214.
  • MILLAR RP, ZHU YF, CHEN C, STRUTHERS RS: Progress towards the development of non-peptide orally-active gonadotropin-releasing hormone (GnRH) antagonists: therapy implications. Br. Med. Bull. (2000) 56:761–772.
  • BOULOUX PM, HANDELSMAN DJ, JOCKENHOVEL F et al.: FSH-CTP STUDY GROUP: First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum. Reprod. (2001) 16:1592–1597.
  • GUO T, DONG G, FITZPATRICK D et al.: Webb ML discovery of potent biaryl diketopiperazine FSH receptor agonists: rapid lead optimization through parallel synthesis. 228th ACS Meeting. Philadelphia, USA (2004).
  • GOUTOPOULOS A, REDDY A, LIAO Y et al.: Proline and pipecolic acid-based agonists of the follicle-stimulating hormone receptor. 226th ACS Meeting. New York, USA (2003).
  • Arena: UBS Global Lifi Sciences Conference 2003. Arena Pharmaceuticals, Inc. Company Presentation (2003).
  • JETTER J, KAO W, ROGERS J et al.: Synthesis and in vitro biology of novel 5-alkylated thiazolidinones as FSH agonists. 226th ACS Meeting. New York (2003).
  • KOCHENDOERFER G: Glycopegylated FSH. 3rd International Conference (Part I) in Protein & Peptide Drug Delivery. Philadelphia, PA, USA (2003).
  • Inhale product development update. IDdb Meeting. London, UK (1997).
  • Serono SA. Annual report 2003. Serono SA (2004).
  • NORMAN P: Org 43553. 12th RSC-SCI Symposium (Part III) Medicinal Chemistry. Cambridge, UK (2003).
  • VAN STRATEN NC, SCHOONUS-GERRITSMA GG, VAN SOMEREN R: The first orally active low molecular weight agonists for the LH receptor: thienopyrfirnfidines with therapeutic potential for ovulation induction. Draaijer Chembiochem. (2002).
  • ARMER RE, SMELT KH: Non-peptidic GnRH receptor antagonists. Curr. Med. Chem. (2004) 11:3017–3028.
  • ••An up to date systematic review of non-peptide oral GnRH-receptor antagonist.
  • SASAKI S, CHO N, NARA Y et al.: Discovery of a thieno12,3-01pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. J. Med. Chem. (2003) 46:113–124.
  • ZHU YF, GUO Z, GROSS TD, GAO Y et al.: Design and structure-activity relationships of 2-alky1-3-aminomethy1-6-(3-methoxypheny1)-7-methy1-8-(2-fluoro-benzyfiimidazolo11,2-alpyrimid-5-ones as potent GnRH receptor antagonists. J. Med. Chem. (2003) 46:1769–1772.
  • TUCCI FC, ZHU YF, GUO Z et al.: 3-(2-aminoalkyl)-1-(2,6-difluorobenzy1)-5- (2-fluoro-3-methoxypheny1)-6-methyl-uracils as orally bioavailable antagonists of the human gonadotropin releasing hormone receptor. J. Med. Chem. (2004) 47:3483–3486.
  • JIANG J, DEVITA JR, GOULET MT et al.: Syntheses and structure-activity relationships studies of Piperidine-substituted quiniolones as non-peptide gonadotropin releasing hormone antagonists. National Medicinal Chemistry Symposium. (2002).
  • METCALF D:. The unsolved enigmas of leukemia inhibitory factor. Stem Cells (2003) 21:5–14.
  • ••This review illustrates the potentialimplications of LIF in infertility.
  • BRINSDEN PR, NDUKWE G, ENGRAND P et al.: Does recombinant human leukaemia inhibitory factor improve implantation in women with recurrent failure of assisted reproduction treatment? Hum. Reprod (2003) 18: 18.
  • TREAD WAY DR, BURAGLIO M, HEMSEY G, DENTON G: A Phase I study of the pharmacodynamic and safety of single - and multiple-dose anastrozole in healthy, premenopausal female volunteers. Fertil Steril (2004) 82:1587–1593.
  • MITWALLY MF, CASPER RF: Aromatase inhibition reduces gonadotropin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum. Reprod (2003) 18:1588–1597.
  • FATEMI HM, KOLIBIANAKIS E, TOURNAYE H, CAMUS M, VAN STEIRTEGHEM AC, DEVROEY P: Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod. Biomed. Online (2003) 7:543–546.
  • GRONDAHL C, BREINHOLT J, WAHL P et al.: Physiology of meiosis-activating sterol: endogenous formation and mode of action. Hum. Reprod. (2003) 18:122–129.
  • BERGH C, LOFT A. LUNDIN K et al.:CEMAS II Study Group: Chromosomal abnormality rate in human pre-embryos derived from in vitro fertilization cycles cultured in the presence of follicular-fluid meiosis activating sterol (FF-MAS). Hum. Reprod (2004) 1:2109–2117.
  • PALMER S, CAMPEN CA, ALLAN GF et al.: Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity. J. Steroid Biochem. MoL Biol. (2000) 75:33–42.
  • ARALDI GL, MAJGIER-BARANOWSKA H, BRUGGER N et al.: Design synthesis and biological evaluation of novel aza-prostaglandins derivatives analogs of 2 as selective EP 2 and EP 2 receptors agonists. 228th ACS Meeting. Philadelphia (2004).
  • WELT CK, CT-JAN JL, BULLEN J et al.:Recombinant human leptin in women with hypothalamic amenorrhea. N EngL J. Med. (2004) 351:987-997. An impressive study about the role of recombinant human leptin.
  • HAYES ES: Biology of primate relaxin: aparacrine signal in early pregnancy. Elrod. Biol. EndocrinoL (2004) 16:36.

Websites

  • http://www.serono.com Serono web site. Drug development pipeline: ProLease. Serono SA (2001).
  • http://www.neurocrine.com/html-clin_gnrh.html Neurocrine Biosciences website (2005).
  • http://www.ferring.com/site/ferring_com/ view.as?ID=250. Ferring Pipeline. Endometrin (FE999913).
  • http://www.ardana.co.uk/clinicaldev.html Ardana website release (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.